Radiomics
Radiomics is an AI-powered clinical research organization that applies deep learning and radiomics to medical imaging analysis, supporting biotech and pharma companies in oncology drug development through its Ikonics platform and clinical trial imaging services.
- Company typePrivate
- Founded2016
- HeadquartersLiège, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Radiomics does
Radiomics (legally Radiomics.bio, headquartered in Liège, Belgium) is an AI-powered clinical research organization founded in 2016 that applies deep learning, machine learning, and federated learning to extract quantitative imaging biomarkers from standard-of-care medical images (CT, PET, MRI) for oncology drug development. The company was established by the researchers who coined the term "radiomics" and published seminal work in Nature, and today serves biotech and pharmaceutical companies across all stages of clinical development, from early-phase mechanism-of-action studies through late-phase outcome prediction. Its core technical asset is the proprietary Ikonics® platform, a fully integrated image management system that handles data acquisition, AI-driven segmentation, manual review workflows, feature quantification, and full auditability for regulatory-grade clinical trial imaging.
Radiomics offers five clinical research services bundled around Ikonics: Disease Characterization, Response Evaluation, Response Characterization, Outcome Prediction, and Central Imaging Services (including RECIST/PERCIST/RANO assessments). Its go-to-market is exclusively B2B enterprise sales targeting pharma and biotech clinical development teams, supplemented by active participation at major oncology conferences (ESMO, SITC, ASCO). Revenue is generated through project-based professional services contracts and Software as a Medical Device (SaMD) licensing, with pricing negotiated directly based on trial scope and complexity. Named customers include AstraZeneca (LECOMTE study on ILD/pneumonitis prediction), iOnctura, InhaTarget, DeuterOncology, and academic centers such as Jewish General Hospital/McGill.
The company operates from an 800m² headquarters at LégiaPark in Liège (since September 2022) and a wholly-owned North American subsidiary in Toronto (established 2022), with primary investor Noshaq Group (Belgian institutional investor). Radiomics holds ISO 13485 certification (since January 2022) for SaMD design and development, ISO 27001 certification (since January 2023) for information security, and is GDPR-compliant. The board was reconstituted in February 2025 with Dr. Jan Groen as Chairman, reflecting preparation for a scale-up phase anchored on partnerships with top-tier pharma clients.
Radiomics firmographics
Firmographics- Name
- Radiomics
- Legal name
- Radiomics.bio
- Website
- https://radiomics.bio
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Radiomics is an AI-powered clinical research organization that applies deep learning and radiomics to medical imaging analysis, supporting biotech and pharma companies in oncology drug development through its Ikonics platform and clinical trial imaging services.
- Ownership category
- akta.pro rank
Radiomics industry classification
Industry- Product category
- Medical Imaging Software & Clinical Trial Imaging Services
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)
Keywords
Where Radiomics is headquartered
LocationHeadquarters
- HQ city
- Liège
- HQ country
- Belgium
- HQ region
- Europe
Offices2 records
Markets served
Radiomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Clinical Research Imaging Services: Radiomics.bio provides advanced image analysis services to biotech and pharma companies for clinical trials. Services include disease characterization, response evaluation, response characterization, outcome prediction, and central imaging services. Revenue is generated through project-based contracts for clinical trial support across all phases of drug development.
- Software as a Medical Device (SaMD): The company develops software for medical devices used for diagnosis, prognosis, or prediction of disease progression assessed through routine clinical imaging, compliant with ISO 13485 standards.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Radiomics product offering
Product offeringCore offering
Radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization that sells clinical trial imaging analysis services and proprietary Software as a Medical Device (SaMD) to pharmaceutical and biotech companies. Its core technology, the Ikonics® platform, extracts quantitative radiomic biomarkers from standard-of-care CT, PET, and MRI images to quantify treatment response, validate drug mechanisms of action, and predict clinical outcomes across all phases of oncology drug development.
Product overview
Radiomics is an AI-powered medical imaging clinical research organization offering a unified portfolio consisting of its proprietary Ikonics® platform plus clinical research services. The Ikonics® platform is a fully integrated image management platform that streamlines image collection, centralizes image quality assessment, and enables radiomic feature quantification. This core technology platform is combined with five clinical service offerings: Disease Characterization, Response Evaluation, Response Characterization, Outcome Prediction, and Central Imaging Services. Together, these enable biotech and pharma companies to extract quantitative imaging biomarkers from medical images for insight-based decision making across all phases of clinical drug development.
Differentiator
Problem solved
Functional benefit
Brands
- Ikonics: AI-powered fully integrated image management platform that streamlines image collection and centralizes image quality assessment for enhanced efficiency in radiomic analysis.
Products and services
- Ikonics Platform Fully integrated proprietary image management platform that streamlines image collection, centralizes image quality assessment, and manages the radiomics pipeline from data acquisition to imaging feature quantification. Includes secure storage linked to sFTP, AI image segmentation models, manual review workflows, real-time results, and full traceability and auditability. Used by biotech and pharma companies as the core technology layer for clinical trial imaging analysis.
- Disease Characterization Services Service that characterizes disease using volumetric analysis and radiomic imaging features to enhance understanding of disease at patient, organ, or lesion level for insightful and cost-effective clinical trial designs. Targeted at biotech and pharma sponsors.
- Response Evaluation Services Service that quantifies treatment response by measuring biological response and validating mechanisms of action through evaluation of phenotypic and anatomical changes of lesions in response to treatment, per arm, per dose, per indication. Enables objective decisions based on drug success potential for each phase of clinical development.
- Response Characterization Services Service that characterizes biological response to explore and validate drug mechanisms of action by fully quantifying the effect of therapeutics in selected organs or through total tumor burden analysis.
- Outcome Prediction Services Service that predicts disease progression, treatment response, and clinical outcomes using imaging and clinical data to obtain early insights during clinical trials for decision-making, including identification of responders vs non-responders and adverse event risk such as ILD/pneumonitis.
- Central Imaging Services Expert central imaging lab services including image protocol optimization, centralized storage, centralized imaging review, and standard assessment methodologies such as RECIST suite, PERCIST, and RANO assessment, conducted in compliance with regulatory and privacy requirements.
Quantifiable outcome
- Delta-radiomics signature identified patients with clinical benefit at 6 months with AUC of 0.8 (95% CI: 0.65-0.95) on external test dataset
- +3 more outcomes
Companies that use Radiomics
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Radiomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
Radiomics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- AstraZenecacoreAstraZeneca commissioned radiomics.bio to develop AI models capable of detecting and predicting interstitial lung disease/pneumonitis risk in cancer patients. The LECOMTE study uses past clinical trial data and Real-World Evidence combined with radiomic imaging data. Promising results were presented at ESMO 2024 showing the model could successfully identify symptomatic pneumonitis in NSCLC patients treated with AstraZeneca immunotherapy.
- Jewish General Hospital / McGill Centre for Translational Research in CancercoreDigital health pilot project 'Digital Health to Advance and Support Precision Oncology' supported by $358,825 grant from Quebec MEIE. Project integrates medical images, pathology, molecular and clinical data for precision medicine in cancer care, aiming to accelerate patient access to new treatments.
- Exactis InnovationcoreNational Centre of Excellence in Personalized Medicine partnership for the pilot project at Jewish General Hospital, contributing to the PMT (Personalize My Treatment) patient registry with multi-modal data integration.
- OROT - CIUSSS West-Central MontrealminorConnected health innovation hub of CIUSSS West-Central Montreal participating in the precision oncology pilot project.
- TransMedTech InstituteminorContributed $75,000 to the precision oncology pilot project as part of the MEDTEQ+ IMPACT program.
- DeuterOncologycoreCollaboration awarded 478,000 EUR SPW Win4Company grant for development and validation of AI-based CT imaging biomarker as companion diagnostic for DO-2, a deuterated MET kinase inhibitor. Project combines DeuterOncology's cancer research expertise with Radiomics' advanced AI image analysis to identify lung cancer patients with MET gene alterations.
- Three Lakes FoundationminorCollaboration on B4PF initiative for early diagnosis of interstitial lung disease/pulmonary fibrosis (ILD/PF). Three Lakes Foundation brings together academia, clinicians and industry to identify imaging insights for early detection, with Radiomics providing radiomic expertise.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Radiomics competitors and assessment
Company assessmentDirect peers
- Median Technologies: Imaging CRO that provides AI-powered imaging biomarkers and central imaging services for oncology clinical trials. Directly comparable to Radiomics' business model of combining AI imaging analytics with pharma/biotech trial services, though larger and publicly listed.
- IXICO: UK-based imaging CRO providing AI-enabled biomarker analysis and central reading services for neuroscience and oncology clinical trials. Highly comparable in serving pharma/biotech with quantitative imaging endpoints and validated image-analysis workflows.
- Owkin: AI-for-drug-discovery platform that partners with pharma to deploy AI on multimodal clinical and imaging data for trial optimization and biomarker discovery. Directly comparable B2B AI-pharma model with imaging and multi-modal analytics components.
- Aignostics: Berlin-based AI pathology/imaging company building foundation models for pharma R&D and clinical trials, with a comparable B2B AI biomarker model. Direct overlap in serving pharma/biotech sponsors with AI-derived imaging biomarkers.
- Image Analysis Group (IAG): Specialist imaging CRO offering quantitative imaging biomarker services for clinical trials across therapeutic areas. Closely matches Radiomics' positioning as an expert imaging partner for pharma/biotech trial sponsors.
Emerging players
- Perspectum: AI medical imaging company developing quantitative imaging biomarkers, primarily in metabolic and fibrotic disease, for pharma R&D and clinical practice. Adjacent competitor with overlapping biomarker-discovery model but different therapeutic focus.
- Lunit: AI medical imaging company with FDA-cleared oncology and chest imaging AI products and pharma/biopharma partnerships. Comparable in applying deep learning to medical imaging but with broader diagnostic-product commercialization.
- Annalise.ai: AI medical imaging company offering comprehensive radiology AI solutions across multiple modalities and clinical workflows. Adjacent competitor in AI medical imaging but focused on diagnostic clinical use rather than pharma trial services.
Broad incumbents
- Philips (IntelliSpace AI): Global medical imaging OEM with embedded AI imaging capabilities sold to hospitals and indirectly used in pharma trials. Larger incumbent with overlapping AI imaging capability but as part of a much broader portfolio rather than a focused radiomics niche.
- GE HealthCare (Edison AI): Major medical imaging OEM with AI-enabled imaging platforms and pharma-services adjacencies (e.g., MIM Software). Broad incumbent providing AI imaging infrastructure that competes indirectly with specialist radiomics CROs for pharma spend.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Radiomics social profiles
Digital presenceRadiomics compliance and trust
Trust signalCompliance3 records
Radiomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Radiomics leadership team
Management profileNumber of profiles
Profiles7 records
Radiomics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Radiomics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Radiomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Radiomics
What does Radiomics do?
Radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization that sells clinical trial imaging analysis services and proprietary Software as a Medical Device (SaMD) to pharmaceutical and biotech companies. Its core technology, the Ikonics® platform, extracts quantitative radiomic biomarkers from standard-of-care CT, PET, and MRI images to quantify treatment response, validate drug mechanisms of action, and predict clinical outcomes across all phases of oncology drug development.
Is Radiomics a public or private company?
Radiomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Radiomics founded?
Radiomics was founded in 2016. It employs 11 to 50 people.
Where is Radiomics based?
Radiomics is headquartered in Liège, Belgium, in the Europe region.
How does Radiomics make money?
Two revenue lines are on record. Clinical Research Imaging Services are the primary driver. The others are software as a Medical Device (SaMD).
Who are Radiomics's main competitors?
Direct peers on record are Median Technologies, IXICO, Owkin, Aignostics and Image Analysis Group (IAG). Emerging players are Perspectum, Lunit and Annalise.ai. Broad incumbents are Philips (IntelliSpace AI) and GE HealthCare (Edison AI).
Does Radiomics have an API?
No public API is recorded for Radiomics.
What industry is Radiomics in?
Radiomics's product category is Medical Imaging Software & Clinical Trial Imaging Services. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 621511 and its SIC code is 8071.